Government Affairs Director - Asia Region
About the job
- A bachelor's degree in Political Science, Public Policy, International Relations, Law, Economics, Healthcare Policy, or a related field is required.
- At least 10 years of experience in government affairs, healthcare policy, public policy, market access policy, trade policy, or related strategic policy roles.
- Demonstrated experience working across Asia Pacific or other multinational regional environments.
- Experience engaging with government officials, policymakers, trade associations, and healthcare stakeholders across multiple markets.
- Proven ability to influence policy discussions and navigate complex healthcare and political environments.
- Experience operating effectively within highly matrixed global organizations.
- Ability to anticipate policy developments and translate complex external dynamics into actionable regional strategies and business insights.
- Strong understanding of healthcare policy, pricing, reimbursement, intellectual property, trade, and access environments across JAPAC markets.
- Ability to advise senior leaders and support executive engagement through clear strategic communications and policy analysis.
- Ability to coordinate and align affiliate, regional, and global stakeholders around shared priorities and execution plans.
- Ability to develop policy narratives, leadership briefings, and stakeholder messaging for effective external engagement.
- Ability to enable knowledge sharing and best-practice exchange across affiliates.
- Ability to operate effectively in matrixed and multicultural environments and maintain high ethical standards and integrity.
- Lead regional alignment and execution of government affairs and healthcare policy priorities across JAPAC, ensuring coordinated strategies, consistent messaging, and visibility into key risks and opportunities.
- Monitor, analyze, and communicate emerging healthcare policy, geopolitical, trade, intellectual property, and international reference pricing developments relevant to JAPAC markets, assessing implications and risk-mitigation considerations.
- Coordinate with Washington, D.C., global, and ELMAC teams to align policy positions, advocacy priorities, and external messaging.
- Support affiliate government affairs and policy teams in developing strategic narratives, stakeholder engagement plans, and approved messaging for engagement with government officials, payers, trade associations, and industry stakeholders on pricing, reimbursement, intellectual property, biosimilars, tariffs, artificial intelligence, and healthcare system sustainability.
- Prepare regional and affiliate leaders to articulate company perspectives on healthcare policy, trade, pricing, and industry issues through briefing materials, leadership messaging, and strategic guidance.
- Support affiliates in assessing and responding to evolving government-led policy developments through timely policy guidance, cross-market insights, and sharing relevant practices.
- Bring affiliate perspectives, market intelligence, and regional insights into global government affairs and policy discussions to help shape coordinated strategies across markets and regions.
- Develop and maintain strategic policy narratives, leadership briefing materials, stakeholder communications, and engagement content for consistent external engagement across the region.
- Collaborate across regions and with global partners to share insights, align approaches on common policy priorities, and identify trends affecting pricing, access, intellectual property, trade, and healthcare systems.
- Represent the company in regional industry associations, policy forums, and external engagements, contributing to collective advocacy efforts and strengthening policy leadership across JAPAC.
- Communicate policy developments, risks, opportunities, and strategic considerations affecting the business to regional and global leadership.
- Execute activities ethically and in compliance with applicable laws, industry codes, and company policies and procedures.
- An advanced degree, such as an MBA, MPA, public policy degree, law degree, or equivalent.
- Significant experience in the pharmaceutical, biotechnology, healthcare, or life sciences sectors.
- Experience working with U.S. Government officials in embassies, consulates, and Washington, D.C., on trade and other policy issues.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.